A study of Aravive-S6 in acute myeloid leukemia (AML).

Trial Profile

A study of Aravive-S6 in acute myeloid leukemia (AML).

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Aravive S6 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jan 2017 New trial record
    • 10 Jan 2017 According to an Aravive Biologics media release, company is planning to file an IND in late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top